Physician profile
Stephen E Van Horn
NPI 1275622979
$6,434.50
in general payments reported to CMS, 2019-2025
33 companies · $798 in 2025
The $798 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $401 · 2021: $499 · 2022: $902 · 2023: $1,006 · 2024: $1,290 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,404.33 | 2019-2025 | |
| Medtronic, INC. | $1,379.33 | 2021-2025 | Linq II, Micra, Selectsecure |
| Amgen INC. | $592.15 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $487.73 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $340.42 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $230.87 | 2022-2025 | Onpattro |
| Boston Scientific Corporation | $219.01 | 2019-2022 | |
| Pfizer INC. | $199.61 | 2019-2024 | |
| Abbott Laboratories | $166.26 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $154.87 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.66 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $117.97 | 2019 | |
| Merck Sharp & Dohme LLC | $106.77 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $104.19 | 2019 | |
| Inari Medical, INC. | $100.65 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $80.86 | 2019-2022 | |
| Novo Nordisk INC | $79.15 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.37 | 2019-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $64.47 | 2024 | Arcalyst |
| Cvrx, INC. | $40.37 | 2025 | Barostim Neo System |
| Heartflow, INC. | $39.96 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $38.93 | 2019 | |
| Arbor Pharmaceuticals, INC. | $37.83 | 2019-2020 | |
| Chiesi USA, INC. | $36.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.15 | 2022-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $32.06 | 2023 | Arcalyst |
| Biotronik INC. | $29.90 | 2019-2021 | |
| Stryker Corporation | $24.33 | 2025 | Flowtriever |
| Philips North America LLC | $18.46 | 2022 | |
| Glaxosmithkline, LLC. | $15.62 | 2023 | Arexvy, Shingrix |
| Kestra Medical Technology Services, INC. | $15.07 | 2024 | Assure Wcd |
| Shockwave Medical, INC | $14.73 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Van Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.